Shattuck Labs (STTK) Stock Forecast & Price Target

Shattuck Labs is attractive fundamentally because SL-325 has already shown a compelling Phase 1 profile with only a 3.7% ADA rate, full DR3 occupancy at low doses, months-long receptor blockade, and all treatment-related adverse events limited to Grade 1, which materially de-risks the mechanism. Its decision to expand into hidradenitis suppurativa is supported by Merck’s positive TL1A-class data, implying direct clinical validation of the TL1A/DR3 pathway and creating an additional value driver beyond Crohn’s disease, ulcerative colitis, and other IBD opportunities. Financially, the company ended 2Q26 with $208.3 million in cash, is expected to fund operations into 2029, and has a broad pipeline that includes SL-846 and SL-425, strengthening long-term optionality.

Shattuck Labs is burdened by a high-risk pipeline in which SL-325 and other DR3 programs could fail in clinical or regulatory development, show weak efficacy, trigger immunogenicity or safety issues, or face manufacturing setbacks that delay progress. The company also faces intense competition in IBD and related inflammatory diseases from approved therapies and larger rivals in TL1A, making differentiation and commercial uptake uncertain. Financially, it is not expected to be profitable for several years and may need additional capital on unfavorable terms, while patent uncertainty and potential infringement risk add further downside.